Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.
北卡羅來納州達勒姆，2024年5月30日（GLOBE NEWSWIRE）——以開發有效改善和延長面臨致命疾病的患者壽命的藥物爲使命的生物製藥公司Chimerix（納斯達克股票代碼：CMRX）今天宣佈，首席執行官邁克·安德里奧爾將於2024年6月6日星期四下午3點參加傑富瑞全球醫療保健會議的爐邊談話。美國東部時間。
An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
小組討論的網絡音頻直播將在Chimerix網站的投資者關係欄目上播出，網址爲 ir.chimerix.com，將在那裏存檔大約 90 天。
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
關於 Chimerix
Chimerix是一家生物製藥公司，其使命是開發能夠有效改善和延長面臨致命疾病的患者壽命的藥物。該公司最先進的臨床階段開發項目 ONC201 正在開發針對 H3 k27M 突變神經膠質瘤。
CONTACT:
聯繫人：
Will O'Connor
Stern Investor Relations
212-362-1200
will@sternir.com
威爾·奧康納
斯特恩投資者關係
212-362-1200
will@sternir.com
Source: Chimerix, Inc.
來源：Chimerix, Inc.